This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Nov;10(11):2019.

doi: 10.1158/1535-7163.MCT-11-0697.

The discovery of lapatinib (GW572016)

David Rusnak¹, Tona M Gilmer

Affiliations

PMID: 22072804
DOI: 10.1158/1535-7163.MCT-11-0697

Comment

The discovery of lapatinib (GW572016)

David Rusnak et al. Mol Cancer Ther. 2011 Nov.

. 2011 Nov;10(11):2019.

doi: 10.1158/1535-7163.MCT-11-0697.

Authors

David Rusnak¹, Tona M Gilmer

Affiliation

¹ BioAgilytix Labs, Inc., Durham, NC, USA.

PMID: 22072804
DOI: 10.1158/1535-7163.MCT-11-0697

No abstract available

PubMed Disclaimer

Comment on

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM. Rusnak DW, et al. Mol Cancer Ther. 2001 Dec;1(2):85-94. Mol Cancer Ther. 2001. PMID: 12467226

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems